VitaNova Life Sciences Corporation VNOV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.04% | 13.65% | 154.79% | 187.50% | 291.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.04% | 13.65% | 154.79% | 187.50% | 291.27% |
| Cost of Revenue | 118.27% | 94.67% | 187.53% | 206.14% | 375.78% |
| Gross Profit | -44.49% | -42.21% | 134.23% | 176.30% | 248.48% |
| SG&A Expenses | 173.91% | 146.91% | 47.77% | 19.21% | 31.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 131.83% | 107.88% | 123.32% | 114.47% | 190.24% |
| Operating Income | -107.06% | -99.70% | 233.28% | 391.79% | 562.36% |
| Income Before Tax | -106.83% | -99.45% | 235.01% | 394.25% | 559.84% |
| Income Tax Expenses | -91.33% | -87.56% | 225.05% | 282.39% | 378.85% |
| Earnings from Continuing Operations | -113.29% | -104.40% | 241.46% | 470.63% | 682.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.29% | -104.40% | 241.46% | 470.63% | 682.88% |
| EBIT | -107.06% | -99.70% | 233.28% | 391.79% | 562.36% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -113.29% | -104.41% | 241.22% | 409.85% | 766.39% |
| Normalized Basic EPS | -106.90% | -99.45% | 233.96% | 359.02% | 596.95% |
| EPS Diluted | -113.29% | -104.41% | 241.22% | 409.85% | 766.39% |
| Normalized Diluted EPS | -106.90% | -99.45% | 233.96% | 359.02% | 596.95% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 23.34% | 61.44% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 23.34% | 61.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |